Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.22

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $16.22.

FOLD has been the subject of a number of analyst reports. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. The Goldman Sachs Group lowered their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Friday, May 2nd.

Amicus Therapeutics Trading Up 3.2%

FOLD traded up $0.20 during midday trading on Wednesday, hitting $6.42. 5,592,318 shares of the company were exchanged, compared to its average volume of 3,202,054. The firm has a market capitalization of $1.98 billion, a P/E ratio of -71.33 and a beta of 0.51. Amicus Therapeutics has a 1-year low of $5.51 and a 1-year high of $12.65. The firm's 50 day moving average price is $6.12 and its 200-day moving average price is $7.85. The company has a quick ratio of 2.47, a current ratio of 3.34 and a debt-to-equity ratio of 2.02.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. lifted its position in Amicus Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 1,280 shares in the last quarter. Diversified Trust Co lifted its position in Amicus Therapeutics by 2.2% in the 1st quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after acquiring an additional 1,784 shares in the last quarter. Tempus Wealth Planning LLC lifted its position in Amicus Therapeutics by 7.2% in the 1st quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock valued at $241,000 after acquiring an additional 1,990 shares in the last quarter. Xponance Inc. lifted its position in Amicus Therapeutics by 11.9% in the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 2,249 shares in the last quarter. Finally, Covestor Ltd lifted its position in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.